WIN-Partners Co., Ltd. (3183) AI Stock Analysis

• Market Cap: ¥37.95B
• Dividend Yield: 3.93%
• Average Volume (3M): 16.25K
• Price to Earnings (P/E): 18.8
• Beta (1Y): 0.75
• Revenue Growth: 11.04%
• EPS Growth: 20.33%
• Country: JP
• Employees: 629
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Distribution
• EPS (TTM): 21.16
• Shares Outstanding: 30,503,310
• 10 Day Avg. Volume: 16,730
• 30 Day Avg. Volume: 16,253
• PEG Ratio: 5.24
• Price to Book (P/B): 1.49
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 70 Outperform
• Price Target: ―

WIN-Partners Co., Ltd. shows strong financial health with a solid income statement and balance sheet. However, the lack of recent operating cash flow data is concerning. Technically, the stock exhibits bearish trends, which could impact short-term performance. The reasonable P/E ratio and high dividend yield provide a solid valuation, appealing to long-term investors. The overall score reflects the company's robust fundamentals but is tempered by technical weaknesses and cash flow concerns.

WIN-Partners Co., Ltd. Business Overview & Revenue Model

Company Description

WIN-Partners Co., Ltd. (3183) is a Japan-based company primarily engaged in the wholesale distribution of medical equipment and devices. The company operates in the medical and healthcare sectors, offering a wide range of products including diagnostic imaging equipment, therapeutic apparatus, surgical equipment, and other medical supplies. WIN-Partners Co., Ltd. serves hospitals, clinics, and medical professionals, providing them with essential tools for patient care and medical procedures.

How the Company Makes Money

WIN-Partners Co., Ltd. generates revenue primarily through the sale of medical equipment and devices to healthcare institutions such as hospitals and clinics. The company earns money by acting as a distributor, sourcing products from various manufacturers and supplying them to healthcare providers. Key revenue streams include the sale of diagnostic imaging equipment, surgical tools, and other medical devices. Strategic partnerships with leading medical equipment manufacturers and maintaining a robust distribution network are significant factors contributing to its earnings. Additionally, the company may offer after-sales services, maintenance, and support, which can also be a source of revenue.

WIN-Partners Co., Ltd. Financial Statement Overview

Summary

WIN-Partners Co., Ltd. demonstrates strong financial performance with consistent revenue growth and profitability, a robust balance sheet free of debt, and substantial equity. However, the cash flow statement requires attention due to the lack of recent data, which poses a potential risk.

Income Statement

WIN-Partners Co., Ltd. reports a strong income statement with consistent revenue growth, evidenced by a TTM revenue increase of 3.73% from the previous annual period. The company maintains healthy profit margins, with a TTM gross profit margin of 12.09% and a net profit margin of 2.38%. Additionally, the EBIT margin stands at 3.42% and the EBITDA margin is 2.14%. These figures indicate robust operational efficiency and profitability, though there is a slight decline in EBITDA margin compared to previous periods.

Balance Sheet

The balance sheet of WIN-Partners Co., Ltd. is notably strong, with zero total debt, resulting in an exceptional debt-to-equity ratio. The return on equity (ROE) is 8.03% for the TTM, reflecting effective use of equity to generate profits. The equity ratio is substantial at 50.86%, indicating a solid capital structure with significant equity backing. The company's high cash reserves further enhance its financial stability and risk profile.

Cash Flow

The cash flow statement reveals some areas of concern for WIN-Partners Co., Ltd. The operating cash flow in the TTM is reported as zero, which could be due to reporting timing or operational issues. Historically, the company has shown positive cash flow generation, with a notable free cash flow growth rate from negative to positive in the prior year. However, the absence of recent operating and investing cash flow data limits a comprehensive analysis.

Breakdown	TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement
Total Revenue	79.94B	77.06B	70.85B	66.39B	62.12B	64.54B
Gross Profit	9.67B	9.53B	8.66B	8.52B	7.74B	8.17B
EBITDA	1.71B	2.92B	3.11B	2.82B	2.45B	2.85B
Net Income	1.91B	1.84B	2.05B	1.83B	1.54B	1.87B
Balance Sheet
Total Assets	15.09B	47.73B	43.88B	41.56B	40.19B	38.63B
Cash, Cash Equivalents and Short-Term Investments	3.93B	18.16B	16.77B	15.57B	17.12B	17.50B
Total Debt	2.60B	0.00	0.00	0.00	0.00	0.00
Total Liabilities	8.93B	24.34B	21.10B	19.84B	19.05B	18.13B
Stockholders Equity	6.16B	23.39B	22.78B	21.72B	21.14B	20.51B
Cash Flow
Free Cash Flow	0.00	2.54B	-525.17M	-136.90M	673.91M	3.11B
Operating Cash Flow	0.00	3.04B	445.15M	2.62B	1.85B	3.22B
Investing Cash Flow	0.00	-219.47M	1.92B	-2.89B	-1.28B	-94.97M
Financing Cash Flow	0.00	-1.45B	-1.16B	-1.28B	-947.37M	-918.66M

WIN-Partners Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1315.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3183, the sentiment is Positive. The current price of 1315 is below the 20-day moving average (MA) of 1333.95, below the 50-day MA of 1316.34, and above the 200-day MA of 1264.27, indicating a neutral trend. The MACD of 2.93 indicates Positive momentum. The RSI at 48.65 is Neutral, neither overbought nor oversold. The STOCH value of 16.36 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3183.

WIN-Partners Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3023	76 Outperform	¥14.66B	7.64		5.24%	-4.83%	7.20%
3391	71 Outperform	$555.84B	25.47	4.93%	3.92%	4.63%	-47.30%
3183	70 Outperform	¥37.95B	18.77		3.93%	11.04%	20.33%
2784	69 Neutral	¥379.27B	13.47	5.65%	3.22%	3.59%	-5.42%
3167	68 Neutral	¥130.60B	14.13		3.41%	5.17%	8.65%
Sector *	64 Neutral	¥338.86B	10.95	-2.99%	2.58%	11.77%	-10.17%
3341	64 Neutral	$90.73B	67.26	2.35%	0.80%	5.94%	-45.43%